| Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape LA Emens, PA Ascierto, PK Darcy, S Demaria, AMM Eggermont, ... European journal of cancer 81, 116-129, 2017 | 561 | 2017 |
| Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer JN Graff, JJ Alumkal, CG Drake, GV Thomas, WL Redmond, M Farhad, ... Oncotarget, 2016 | 376 | 2016 |
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ... The Lancet Oncology 19 (5), 694-704, 2018 | 363 | 2018 |
| Peripheral tolerance of CD8 T lymphocytes WL Redmond, LA Sherman Immunity 22 (3), 275-284, 2005 | 328 | 2005 |
| OX40 agonists and combination immunotherapy: putting the pedal to the metal SN Linch, MJ McNamara, WL Redmond Frontiers in oncology 5, 34, 2015 | 283 | 2015 |
| Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen J Hernandez, S Aung, WL Redmond, LA Sherman The Journal of experimental medicine 194 (6), 707-718, 2001 | 273 | 2001 |
| The role of OX40-mediated co-stimulation in T-cell activation and survival WL Redmond, CE Ruby, AD Weinberg Critical Reviews™ in Immunology 29 (3), 2009 | 230 | 2009 |
| OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor MJ Gough, CE Ruby, WL Redmond, B Dhungel, A Brown, AD Weinberg Cancer research 68 (13), 5206-5215, 2008 | 191 | 2008 |
| Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity WL Redmond, SN Linch, MJ Kasiewicz Cancer immunology research 2 (2), 142-153, 2014 | 181 | 2014 |
| Signaling through OX40 enhances antitumor immunity SM Jensen, LD Maston, MJ Gough, CE Ruby, WL Redmond, M Crittenden, ... Seminars in oncology 37 (5), 524-532, 2010 | 172 | 2010 |
| Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice MJ Gough, MR Crittenden, MC Sarff, P Pang, SK Seung, JT Vetto, HM Hu, ... Journal of immunotherapy 33 (8), 798-809, 2010 | 165 | 2010 |
| The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment M Farhad, AS Rolig, WL Redmond Oncoimmunology 7 (6), e1434467, 2018 | 160 | 2018 |
| Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo WL Redmond, BC Marincek, LA Sherman The Journal of Immunology 174 (4), 2046-2053, 2005 | 129 | 2005 |
| Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist WL Redmond, MJ Gough, B Charbonneau, TL Ratliff, AD Weinberg The Journal of Immunology 179 (11), 7244-7253, 2007 | 105 | 2007 |
| Cutting edge: T cell-mediated pathology in murine Lyme borreliosis MD McKisic, WL Redmond, SW Barthold The Journal of Immunology 164 (12), 6096-6099, 2000 | 101 | 2000 |
| Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses CE Ruby, WL Redmond, D Haley, AD Weinberg European journal of immunology 37 (1), 157-166, 2007 | 100 | 2007 |
| Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice SN Linch, MJ Kasiewicz, MJ McNamara, IF Hilgart-Martiszus, M Farhad, ... Proceedings of the National Academy of Sciences 113 (3), E319-E327, 2016 | 92 | 2016 |
| A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone JN Graff, TM Beer, JJ Alumkal, RE Slottke, WL Redmond, GV Thomas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 89 | 2020 |
| Targeting OX40 and OX40L for the treatment of autoimmunity and cancer WL Redmond, AD Weinberg Critical Reviews™ in Immunology 27 (5), 2007 | 81 | 2007 |
| Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression WL Redmond, T Triplett, K Floyd, AD Weinberg PloS one 7 (4), e34467, 2012 | 58 | 2012 |
Walter UrbaEarle A Chiles Research InstituteDirección de correo verificada de providence.org
